

Date: 11/12/2017

FREEDOM OF INFORMATION REQUEST - Ref: FOI/013782 – Pharmacy transformation programme

Under the Freedom of Information Act could you please provide answers, where possible, to the following:

• In February 2016, the Lord Carter of Coles review “Operational productivity and performance in English NHS acute hospitals: Unwarranted variations” was published. A key requirement of Lord Carter’s report was that all Trusts are required to submit a board approved hospital pharmacy transformation programme (HPTP) plan to NHS Improvement by April 2017. Could you please provide a copy of the Trust’s hospital pharmacy transformation programme (HPTP) plan. If this is not available, please provide a date when it will be published?

For a copy of the plan please contact dgft.foil@nhs.uk

• In section 10, C6 from the document <https://www.england.nhs.uk/wp-content/uploads/2016...> (Page 86), Trusts with relevant specialties are required to produce an Implementation Plan (IP) containing information on Priority 1, 2 & 3 drugs. If applicable, could you please provide your Trusts Implementation Plan related to these drugs? If the plan is not produced yet, please provide a date when it is expected?

• For Trigger 1 of the Hospital Medicine Optimisation CQUIN (Section 10 C5 from the document <https://www.england.nhs.uk/wp-content/uploads/2016...>.) Trusts are required each month to produce a report for benchmarking, evaluating and reporting against the Triggers. Can you please provide all reports produced by your Trust since April 2017.

| MO CQUIN Trigger One Implementation Summary | |
|--|--|
| April 17 | |
| Work Completed | Work Planned for next 4 weeks |
| <ul style="list-style-type: none"> • NHSE meeting on 3rd April 2017 to finalise drugs list for DGHFT – outstanding issues to address (awaiting response from NHSE) • Generic Imatinib switch agreed with Haematologists <ul style="list-style-type: none"> ○ Patient information leaflet developed | <ul style="list-style-type: none"> • Chase NHSE for final drugs list (this will evolve over the course of the CQUIN) • Obtain patient feedback on Imatinib leaflet • Begin patient engagement on Imatinib switch |
| May 17 | |
| Work Completed | Work Planned for next 4 weeks |
| <ul style="list-style-type: none"> • NHSE chased via email on 12th May and 23rd May for final drugs list for DGHFT and to address outstanding issues (awaiting response from NHSE) • Generic Imatinib switch agreed with Haematologists <ul style="list-style-type: none"> ○ Patient information leaflet developed ○ Patient engagement and feedback initiated in preparation for Imatinib switch | <ul style="list-style-type: none"> • Continue to chase NHSE for final drugs list (this will evolve over the course of the CQUIN) • Check progress of patient feedback and engagement for Imatinib switch • Contact NHSE regarding shortage of Caspofungin – this was on the original drugs list for the trust but it is unknown if it will be on the updated list |

June 17

| Work Completed | Work Planned for next 4 weeks |
|---|--|
| <ul style="list-style-type: none"> NHSE chased via email on 20th June for final drugs list for DGHFT and to address outstanding issues Received drugs list on 22nd June, which contains no Q1 drugs for DGHNHSFT – queries sent to NHSE on 23rd June – awaiting response Continued patient feedback and engagement for Imatinib switch Drugs list shows <u>Caspofungin</u> to be implemented in Q3 | <ul style="list-style-type: none"> Continue to chase NHSE regarding queries on Q1 data submission Check progress of patient feedback and engagement for Imatinib switch <ul style="list-style-type: none"> Implement switch for newly diagnosed patients Meet with oncology lead pharmacist |

July 17

| Work Completed | Work Planned for next 4 weeks |
|--|---|
| <ul style="list-style-type: none"> NHSE chased via email on 26th July for final drugs list for DGHFT and to address outstanding issues Received drugs list on 22nd June, which contains no Q1 drugs for DGHNHSFT – queries sent to NHSE on 26th July – awaiting response Drugs list shows <u>Caspofungin</u> to be implemented in Q3 Imatinib switch implemented on 1st July for new and existing patients Meeting with biosimilar rituximab manufacturers and queries raised (<u>Napp</u> and <u>Sandoz</u>) | <ul style="list-style-type: none"> Continue to chase NHSE regarding queries on Q1 data submission Monthly report of Imatinib switching Clinical procurement for rituximab biosimilar switch and begin planning an implementation programme |

August 17

| Work Completed | Work Planned for next 4 weeks |
|---|--|
| <ul style="list-style-type: none"> Imatinib Report – 45% of existing patients switched to generic in July (target 20%), 100% of new patients prescribed generic in July (target 100%) Received drugs list on 22nd June, which contains no Q1 drugs for DGHNHSFT – queries sent to NHSE on 26th July – awaiting response Drugs list shows <u>Caspofungin</u> to be implemented in Q3 Options appraisal for rituximab biosimilar switch | <ul style="list-style-type: none"> Review response from NHSE on Q1 submission <ul style="list-style-type: none"> Invite NHSE to department to work through queries ahead of Q2 submission Monthly report of Imatinib switching Clinical procurement meeting on 6th September 2017 for rituximab biosimilar switch and begin planning an implementation programme |

| September 17 | |
|---|--|
| Work Completed | Work Planned for next 4 weeks |
| <ul style="list-style-type: none"> • Imatinib Report – 75% of existing patients switched to generic in August (target 20%), 100% of new patients prescribed generic in August (target 100%) • Clinical procurement meeting on 6th September 2017 for rituximab biosimilar switch and begin planning an implementation programme • Meeting on 20th September to confirm rituximab biosimilar switch, to be implemented on 1st October 2017 for new patients • Meeting on 21st September to implement <u>Tenofovir</u> switch, procurement have arranged an account with Mylan. | <ul style="list-style-type: none"> • Await response from NHSE on Q1 questions submission <ul style="list-style-type: none"> ○ Invite NHSE again to department to work through queries ahead of Q2 submission • Monthly report of <u>Imatinib</u>, rituximab and <u>Tenofovir</u> switching • Begin implementation of <u>Rixutimab</u> and <u>Tenofovir</u> switch |
| October 17 | |
| Work Completed | Work Planned for next 4 weeks |
| <ul style="list-style-type: none"> • Imatinib Report – 100% of existing patients switched to generic in September (target 20%), 100% of new patients prescribed generic in September (target 100%) • Rituximab biosimilar switch implemented on 1st October 2017 for new patients • <u>Tenofovir</u> biosimilar switch implemented on 1st October 2017 for new patients | <ul style="list-style-type: none"> • Await response from NHSE on Q1 questions and Q2 submission <ul style="list-style-type: none"> ○ NHSE reviewing Q1 and Q2 submissions on 02/11/17, to then invite NHSE to the department for feedback • Monthly report of rituximab and <u>Tenofovir</u> switching |
| November 17 | |
| Work Completed | Work Planned for next 4 weeks |
| <ul style="list-style-type: none"> • <u>Tenofovir</u> report – 100% of new patients being prescribed generic, 26% of existing patients switched to generic. • Received Q1 and Q2 feedback – target met. | <ul style="list-style-type: none"> • Monthly report of rituximab and <u>Tenofovir</u> switching |